Research Links Depression to Early Stages of Alzheimer's
Research at Heinrich-Heine-Universität investigates the role of beta-amyloid dimers in depression and early-stage Alzheimer's. The goal is to develop new therapeutic strategies.
Researchers at the Heinrich-Heine-Universität in Düsseldorf have investigated the connection between beta-amyloid dimers and depression in the early stages of Alzheimer's disease. The two-year project, completed in May 2024, focused on how these soluble protein complexes affect mood and cognition.
The project, led by Dr. Laila Abdel-Hafiz, received €10,000 in funding through the Kurt Kaufmann Prize. The study utilized a mouse model that produces soluble beta-amyloid forms. This model showed mild cognitive deficits, increased anxiety, and changes in brain activity similar to early human Alzheimer's symptoms.
Preliminary findings suggest that beta-amyloid dimers may disrupt the balance of serotonin, the "happiness hormone," in the brain. Serotonin plays a crucial role in regulating depression.
The primary goal of the research was to identify new treatment approaches targeting both early-stage Alzheimer's and its common accompanying symptom, depression. The team tested two different compounds believed to counteract the detrimental effects of beta-amyloid dimers on serotonin. While detailed outcomes were not fully disclosed, the study provides a foundation for novel therapeutic strategies aimed at slowing disease progression and enhancing patient quality of life.
The Alzheimer Forschung Initiative e. V., based in Hannover, supports research endeavors dedicated to understanding the causes of Alzheimer's disease and developing effective treatments.